Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined pneumococcal vaccination in adults treated for acute leukemia or lymphoma
2020-002017-18Phase 4Active
- Sponsor
- CHU de Poitiers
- Start
- Apr 2020
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by CHU de Poitiers. Primary endpoint: Good response to combined vaccination strategy at 4 weeks after completion. Started Apr 2020; status: active.
02
Drugs
pneumococcal 13-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2020-002017-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002017-18.